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IMRT, VMAT and IMPT respectively and the maximum doses 
were 82.5Gy, 87.4Gy and 89.9Gy. On top of the significant 
increase in mean and maximum PTV boost dose obtained for 
IMPT, the PTV(46 Gy) homogeneity can be improved  to a 
median value of 30.4%.  
Conclusion: Dose escalating a FET PET based target volume to 
above 77 Gy in 30 fractions by IMRT, VMAT, and IMPT without 
increasing both the PTV(46 Gy) homogeneity and the mean 
dose to the OAR was found feasible. For IMPT the PTV(46 Gy) 
homogeneity was substantially improved, implicating a 
reduction of the risk of morbidity. 
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Purpose: Published studies concerning radiotherapy at ultra 
high dose rate (Flash) show a possible increase in the 
differential response between normal and tumour tissue 
compared to conventional radiotherapy [1-2]. Since we have 
access to a prototype linac capable of pulsed electron 
irradiation at those dose rates, we have setup a research 
program to investigate the biological effects of Flash 
irradiation on normal tissues and tumours. Irradiations at 
ultra high dose rates means short (< 1 s) beam-on times with 
a very intense beam. This makes the dosimetric precision 
needed for pre-clinical studies rather challenging. The 
overall purpose of our project is to address all technical and 
dosimetric questions related to irradiation at ultra high dose 
rates, along with pre-clinical studies.  
Material and methods: The first step of the program was to 
investigate if the standard types of dosimeters can still be 
used for electron absolute dosimetry in these radiation 
intense conditions, especially for ionization chambers which 
are known to saturate. Hence, dose rate dependence was 
investigated for a wide variety of dosimeters used in 
radiotherapy by studying their response at various dose rates. 
The second step was to investigate the relative biological 
effect. Normal tissue toxicity and GBM response was studied 
in vitro and in mice after whole brain irradiation with Flash 
and at conventional dose rate.  
Results: Four of the tested dosimeters (Radiochromic film 
(Gafchromic EBT3), TLD, Alanine pellets, and a chemical 
dosimeter based on Methyl Viologen) showed no dose rate 
dependence. The response of the Advanced Markus ionization 
chamber (PTW-Freiburg) was measured to depend only on the 
dose-per-pulse and unlike most ion-chambers did not 
saturate completely in our beam. Consequently, the chamber 
can still be used after correction from ion collection 
efficiency (Figure). With the use of these dosimeters we then 
have the precision in dose delivery (uncertainty ≈ 5%) needed 
to perform pre-clinical radiobiological studies. Studies were 
conducted on Neural Stem Cells (NSCs) and showed that the 
neurogenesis was preserved at doses up to 20 Gy with FLASH, 
whereas 10 Gy was sufficient at conventional dose rate to 
totally impair the neurogenesis, at the same time point. The 
preservation of neurogenesis was associated with preserved 
cognitive skills. Studies on GBM response are ongoing.  
   
 
Conclusions: Radiotherapy treatment at ultra high dose rate 
is almost instantaneous (< 1 s) and it could be the next major 
treatment improvement in medical radiation oncology. Our 
dosimetric measurements show that a variety of standard 
dosimeters can still be used for accurate dose determination 
at these dose rates and our first pre-clinical studies show 
that FLASH irradiation induces different responses in the 
brain NSCs compared to irradiation at conventional dose rate. 
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A compact, high-granularity digital calorimeter detector is a 
candidate for a high-speed Bragg Peak detector, for use in 
proton Computed Tomography. Applications range from dose 
plan validation before particle therapy to proton Stopping 
Power Ratio estimates prior to dose planning. Due to the 
large number of pixels the device will be able to cope with 
large particle multiplicities, thus providing a breakthrough in 
rate capabilities. 
The development of this device profits from R&D performed 
for high-energy physics experiments. In this context, a small 
prototype, a silicon/tungsten sandwich calorimeter (4 cm x 4 
cm x 10 cm total volume) with 24 layers of Monolithic Active 
Pixels Sensors (30 µm x 30 µm pixel size) has been 
constructed [2]. As a proof of principle for its application in 
therapy, the prototype has been irradiated with therapeutic 
proton beams ranging in energy from 122 MeV to 190 MeV, 
where the protons are stopped in the detector. A similar 
setup is reproduced in the Monte Carlo code GATE/Geant4 
[3] for validation and optimization. 
Detector performance from these tests will be presented. Of 
importance is the conversion of an energy signal into a 
charge diffused binary signal, which leads to an 
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approximation of the energy deposited by each individual 
proton in each layer. 
A tracking algorithm is able to find the water equivalent path 
length of each individual proton. When this information is 
combined with the approximated energy deposition on each 
layer, an estimate of the incoming proton energy is obtained 
by locating the high energy deposit of the Bragg Peak. 
Results from this analysis, as well as the capabilities of 
alternative setups will be presented, to show the feasibility 
of using such a calorimeter for proton Computed 
Tomography. 
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Purpose: The more selective energy deposition of protons in 
depth is advantageous compared to photons to preserve 
normal tissues. Nevertheless, an even better tissue sparing 
might be possible in proton therapy if combined with the 
well-established tissue preservation of spatially fractionated 
submillimetric beams. This sparing effect has been observed 
in studies performed with synchrotron minibeam 
radiotherapy (MBRT) [1,2].  
The innovative approach proposed here, called proton 
minbeam radiation therapy (pMBRT), was shown to lead to 
favorable dose distributions in Monte Carlo (MC) studies [3]. 
The dose profiles in normal tissue consist in peaks and 
valleys, while the tumour receives a (quasi)-homogenous 
dose distribution [3]. The goal of this study was to implement 
this promising approach at a clinical center, as well as to 
gather a complete set of dosimetric data that will serve to 
guide the ongoing biological experiments [4].  
Material and Methods: The implementation of pMBRT was 
carried out at the Proton Therapy Center in Orsay (ICPO). 100 
MeV-proton minibeams (400 and 700 μm-width) were 
generated by means of a multislit collimator. The dose 
distributions (depth dose curves, lateral profiles, peak-to-
valley dose ratios (PVDR) [6], beam widths and output 
factors) were measured by means of Gafchromic EBT3 films 
and the new PTW microDiamond detector [5].  
In parallel, a very first MC-based calculation engine for 
pMBRT is under development using Gate v7.0. 
Results: The experimental data confirm that a spatial 
fractionation of the dose is maintained in normal tissues 
(PVDR up to 7) while a quasi-homogeneous dose distribution 
is reached at the Bragg peak location, in agreement with 
theoretical predictions [3]. The reduced penumbras (600-
1100 μm) in healthy tissue make pMBRT a good candidate for 
radiosurgery applications.  
Similar results were obtained using either EBT3 films or the 
PTW microDiamond detector. The preliminary MC 
calculations were consistent with experimental dose 
distributions.  
Conclusion: This is the first work providing both a complete 
set of dosimetric data in such small proton field sizes and a 
practical implementation of this promising approach using a 
clinical set-up and beam energy. The dose distributions 
showed the potential of this technique, which might lead to a 
reduction of the normal tissue complication probability. 
Animal irradiation experiments are ongoing to confirm the 
normal tissue sparing capability of pMBRT. 
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Purpose: We assessed in vitro and in vivo the relative 
contribution of direct and bystander effects in the 
therapeutic efficacy of RIT using 212Pb-labeled mAbs for 
treating cancer cells.  
Materials and Methods: A-431 cells were in vitro exposed to 
increasing activities (0–0.5 MBq/mL; 37 MBq/mg) of either 
35A7 (anti-CEA), Trastuzumab (anti-HER2) or PX (non-
specific) 212Pb-labeled mAbs. The relative contribution of 
direct and bystander effects was determined using standard 
medium transfer protocol. Biological end points included 
clonogenic survival and DNA double strand breaks (using 
53BP1 and gamma-H2AX immunofluorescence detection) 
measured both in donor (direct effect) and in recipient cells 
(bystander effects). In vivo, nude mice with intraperitoneal 
(i.p.) 2-3 mm A-431 tumour cells xenografts were i.p. 
injected with increasing activities (370–1480 kBq; 37 
MBq/mg) of the above mentioned anti-CEA, anti-HER2 or non-
specific 212Pb-mAbs. Tumour growth was determined and the 
distribution of radioactivity at the tissue level was assessed 
using digital micro-autoradiography (DAR) followed by voxel 
dosimetry. Biological markers including 53BP1 and Ki67 
proteins together with abnormal mitosis were also 
determined on tumour sections. 
Results: In vitro we showed in donor cells the strong efficacy 
of 212Pb-35A7 and 212Pb-trastuzumab mAbs and also to a lower 
extent of 212Pb-PX mAb. Significant bystander cytotoxicity 
was measured in all recipient cells with the three 
radiolabeled mAbs. The complexity of DNA damage (53BP1 
foci) observed in donor cells confirmed the high LET 
cytotoxic effects of 212Pb-mAbs while less complex damage 
were observed in recipient cells. 
In vivo DAR and voxel dosimetry indicated the strong 
heterogeneity in anti-CEA 212Pb-mAbs distribution in tumours. 
Conversely, distribution of anti-HER2 212Pb-mAbs was much 
more homogeneous. These data could explain the lower 
therapeutic efficacy of the latter mAbs compared with anti-
HER2 212Pb-mAbs (median survival of 94 days for anti-CEA 
212Pb-mAbs versus 20 days for control, not reached for anti-
HER2 212Pb-mAbs). Moreover, voxel dosimetry indicated that 
about 30% of the tumours of mice treated with anti-CEA 
212Pb-mAbs received 0Gy. However, we also observed in the 
same tumours, homogeneous formation of DNA damage 
